Analyst consensus rating
Eupraxia Pharmaceuticals Analyst Rating: Strong Buy
EPRX is rated Strong Buy by 10 analysts with a $16.35 target. As of 2026-08-23.
Direct answer
Eupraxia Pharmaceuticals's consensus rating is Strong Buy.
10 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $16.35.
Forecast evidence checked August 23, 2026.
Get free Eupraxia Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $6.73
- Average price target
- $16.35
- High price target
- $25.00
- Low price target
- $11.00
- Low target gap
- +63.4%
- Target upside
- +142.9%
- High target gap
- +271.5%
- Target range width
- 208%
- Consensus rating
- Strong Buy
- Analysts
- 10
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Eupraxia Pharmaceuticals?
Eupraxia Pharmaceuticals has a verified Strong Buy consensus. The same dataset has an average price target of $16.35.
How far are Eupraxia Pharmaceuticals's low and high targets from the recorded price?
The low target implies +63.4%, while the high target implies +271.5%.
How many analysts are included in Eupraxia Pharmaceuticals's consensus?
The verified consensus includes 10 analysts.
How is Eupraxia Pharmaceuticals's target upside or downside calculated?
The average target of $16.35 is divided by the recorded price of $6.73, then one is subtracted to produce +142.9%. This does not guarantee a future return.
When was Eupraxia Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.